FDA Drug Approval Marks a First for a Disease — But It’s Not Autism / MedCity

Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda #autism

Clinicians divided amid growing demand for unproven autism drug

7 hrs / beckershospitalreview / Mariah Taylor

FDA Drug Approval Marks a First for a Disease — But It’s Not Autism

31 hrs / medcitynews / Frank Vinluan

FDA finds little evidence that a generic drug can help people with autism

6 days / medicalxpress

FDA widens use of leucovorin without new trial data

6 days / endpoints / Max Bayer

Sunday, March 15, 2026, 12:22 pm / permalink 20779 / 4 stories in 30 hrs

Related Stories

FDA Abortion Pill Decisions Rooted in Science / 1 month
FDA loosens data restrictions to accelerate drug reviews / 2 months
FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 4 months
FDA launches individualized therapy framework for ultra-rare diseases / 20 days
FDA makes one pivotal trial the default for drug approvals / 25 days
FDA refuses to review Moderna mRNA flu vaccine application / 4 wks
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 2 months

Related Tags

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (14 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (17 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (43 hrs)

more #pharmaceuticals

Public Health

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (17 hrs)

AI improves UK breast-screening detection by about 10% (2 days)

Personalized cessation program doubles quit rates for cervical cancer survivors (2 days)

more #publichealth

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.